TyrosinStudienlage & Dosis

Top-Studien zu Tyrosin

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

1. 01

   Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

   Journal of Biological Chemistry·1996223 einflussreiche Zitationen

   Here, we have studied the activity of a novel protein-tyrosine kinase inhibitor that is selective for the Src family of tyrosine kinases. We have focused our study on the effects of this compound on T cell receptor-induced T cell…

2. 02

   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

   New England Journal of Medicine·2001·n=83214 einflussreiche Zitationen

   <h4>Background</h4>BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be…

3. 03

   mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

   Cancer research·2006200 einflussreiche Zitationen

   Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1…

4. 04

   BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

   Oncogene·2008200 einflussreiche Zitationen

   Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although…

5. 05

   Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

   Nature genetics·2012·n=5200 einflussreiche Zitationen

   Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire…

6. 06

   Therapeutic advances of targeting receptor tyrosine kinases in cancer.

   Signal transduction and targeted therapy·2024200 einflussreiche Zitationen

   Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and…

7. 07

   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

   The Lancet·2005·n=73199 einflussreiche Zitationen

   <h4>Background</h4>Human myeloproliferative disorders form a range of clonal haematological malignant diseases, the main members of which are polycythaemia vera, essential thrombocythaemia, and idiopathic myelofibrosis. The molecular…

8. 08

   AXL signaling in cancer: from molecular insights to targeted therapies.

   Signal transduction and targeted therapy·2025194 einflussreiche Zitationen

   AXL, a member of the TAM receptor family, has emerged as a potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays a significant role in various tumor-promoting pathways,…

9. 09

   Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy.

   Cancers·2020177 einflussreiche Zitationen

   Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in…

10. 10

    Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.

    Oncogene·2009·n=110175 einflussreiche Zitationen

    The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-5' triphosphate-binding site.…